Navigation Links
First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
Date:9/4/2012

SEOUL, South Korea, Sept. 4, 2012 /PRNewswire/ -- Korean researchers, reporting the results of a major study in the Circulation Journal, found that the transplantation adipose (fat) derived stem cells resulted in the regeneration of blood vessels in patients who were otherwise expecting to receive limb amputations due to damaged arteries and lack of blood circulation.

Researchers at Pusan National University, led by Dr. Han Cheol Lee, describe how patients with critical limb ischemia (hereafter, CLI, example of which include Buerger's Disease and diabetic foot ulcers) were injected with adipose tissue-derived mesenchymal stem cell manufactured by RNL BIO.

As a result of the remarkable adipose stem cell process of RNL BIO, researchers found that immediate new blood vessel generation was identified. (The title of article is "Safety and Effect of Adipose Tissue-Derived Stem Cell Implantation in Patients With Critical Limb Ischemia")

CLI results from lack of circulation due to small artery damage and subsequent tissue necrosis. Patients with severe CLI often face limb amputation. Buerger's Disease, or diabetic foot ulcer, are of the same kind. Risk factors are diabetic mellitus, hypertension, high cholesterol and smoking. There is no known cure to date.

Currently percutaneous transluminal angioplasty or PTA may treat 60-70% of patients with CLI, but it doesn't work with those who suffer from Buerger's Disease. Working under approval to conduct compassionate use research of stem cell to treat CLI by intra-muscular injection of adipose tissue derived stem cells in December, 2008 (KFDA IND approval # 1273), the researchers in this study enrolled 15 subjects: 12 with Buerger's Disease, and 3 with Diabetic foot ulcers. 300 million stem cells were injected into each patient's leg.  No complications were observed, even six months after injection.

Only five patients, as they all had expected, required minor amputation during follow-up, and all amputation sites healed completely. At 6 months, significant improvement was noted in pain and in claudication walking distance. Digital subtraction angiography before and 6 months after ATMSC implantation showed formation of numerous vascular collateral networks across affected arteries.

Dr. Jeong-Chan Ra, President of RNL Stem Cell Technology Institute, said, "This new therapy through adipose tissue derived mesenchymal stem cell is expected to offer new hope for patients with CLI, hope that had been difficult to find before."


'/>"/>
SOURCE RNL Stem Cell Technology Institute
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
2. Colbufalos Obtains First Success With Sexed Semen In Buffalo Breeding Industry
3. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
4. Researchers pioneer worlds first HIV/AIDS nanomedicines
5. Bode Technology Offers First Rapid DNA Service Delivering a DNA Profile from Evidentiary Samples in Under 90 Minutes
6. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
7. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2013
8. China Cord Blood Corporation to Report First Quarter of Fiscal 2013 Financial Results
9. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
10. K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court
11. Gevo Doesnt Infringe Butamaxs 017 Patent; Gevo was First to Invent Enzyme in 017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... 24, 2017 (PRWEB) , ... May 24, 2017 ... ... , Medical systems are increasingly being developed with Wi-Fi connectivity to reduce the ... moved from room to room. In addition, compact mobile devices including infusion pumps, ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a leading provider ... the occasion with a strong presence at Bio-IT World Conference & Expo 2017 ... an invitation to all attendees to view posters on the entire range ...
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy Goin is ... Clinical Operations. She brings years of expertise in establishing and leading clinical operations ... as a licensed occupational therapist, through a variety of leadership roles in Clinical ...
(Date:5/22/2017)... ... May 22, 2017 , ... Baltimore biotech ... the Maryland Biohealth community in developing and issuing recommendations to grow Maryland's biohealth ... Innovation Hub by 2023. , The recommendations are contained in ...
Breaking Biology Technology:
(Date:4/17/2017)... 17, 2017 NXT-ID, Inc. (NASDAQ: NXTD ... filing of its 2016 Annual Report on Form 10-K on Thursday ... ... available in the Investor Relations section of the Company,s website at ... website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):